Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+6.04%
$91.00
100% positive prob.
5-Day Prediction
+8.08%
$92.75
100% positive prob.
20-Day Prediction
+6.35%
$91.26
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +6.04% | +8.08% | +6.35% | 100.0% | Pending |
| Q2 2026 | SELL | -0.55% | -9.04% | +0.07% | 100.0% | Pending |
| Q1 2026 | SELL | -0.70% | -9.95% | +1.26% | 100.0% | -4.53% |
| Q4 2025 | SELL | -0.70% | -9.95% | +1.26% | 100.0% | Pending |
SEC 8-K filings with transcript text
Nov 4, 2026 · 100% conf.
1D
+6.04%
$91.00
Act: -3.26%
5D
+8.08%
$92.75
20D
+6.35%
$91.26
2 dnth-ex99_1.htm
Exhibit 99.1
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN)
Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W on track, with top-line results expected in 2H’28
Phase 3 CAPTIVATE trial of claseprubart in CIDP evaluating 300mg/2mL Q2W now conservatively projected to require less than 200 participants in the open-label Part A in order to randomize 128 responders into the placebo-controlled withdrawal Part B portion of the study, with Part A top-line results expected by YE’27 and Part B top-line results expected by YE’28
Phase 2 MoMeNtum trial of claseprubart in MMN top-line results on track for December ’26
DNTH212 continues to advance with Phase 1 single ascending dose (SAD) Part A healthy volunteer preliminary data expected in Q1’27. First SLE patient in Part B of the Phase 1 SAD study was dosed in October, with preliminary results from Part B expected in 2H’27. The Dianthus-led Phase 1 multiple ascending dose (MAD) study is planned to initiate in Q2’27 with preliminary data expected in 2H’27
DNTH312, an internally developed, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL for severe autoimmune diseases, on track to be Phase 1 ready by YE’27
Approximately $1.2 billion of cash as of September 30, 2026 provides expected runway into 2030
New York City and Waltham, Mass., November 4, 2026 – Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the third quarter ending September 30, 2026, and provided an update on other recent business achievements.
“The Dianthus team continues to execute on our strategy to build a best-in-disease neuromuscular franchise with claseprubart across gMG, CIDP, and MMN, while advancing an exciting pipeline of potentially best-in-disease bifunctional fusion proteins with DNTH212 and DNTH312,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. “Following top-line results from our Phase 2 MoMeNtum trial of claseprubart in December, we plan to quickly initiate a Phase 3 trial in MMN in 2027. MMN represents a significant market opportunity, characterized by high unmet needs and limited competition. IVIg is the only approved treatment for patients with MMN, and the lack of patient and physician satisfaction with IVIg presents a meaningful opportunity for claseprubart, given its unique potential for a differentiated, best-in-disease profile due to potent inhibition of the classical pathway and
1
www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036
preservation of the lectin and alternative pathways while targeting a patient-friendly, 300mg/2mL, self-administered subcutaneous autoinjector once every two weeks.”
Claseprubart: Potential Best-in-Disease aC1s Inhibitor for Neuromuscular Diseases
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks. Claseprubart has the potential to be a best-in-disease pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
Generalized Myasthenia Gravis (gMG)
• Phase 3 EMERGE trial on track with top-line results expected in 2H’28: A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL S.C. Q2W and 300mg/2mL S.C. Q4W in gMG patients was initiated in June, with top-line results expected in 2H’28.
• MaGic OLE data presented at AANEM: Results from the Phase 2 MaGic open-label extension (OLE) were presented at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, September 29 to October 2, 2026, and demonstrated sustained efficacy and a continued favorable safety profile for claseprubart in gMG.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• 75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial, exceeding the target response rate of 50% or greater based on precedent set with aC1s inhibition. Results were consistent and clinically meaningful across multiple efficacy measures. Claseprubart was generally well tolerated with no related
Aug 4, 2026 · 100% conf.
1D
-0.55%
$109.79
Act: +1.90%
5D
-9.04%
$100.42
20D
+0.07%
$110.48
2 dnth-ex99_1.htm
Exhibit 99.1
Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN)
Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June ‘26, with top-line results anticipated in 2H’28
75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial of claseprubart in CIDP, with Part B top-line guidance expected by YE’26
Phase 2 MoMeNtum trial of claseprubart in MMN exceeded its original enrollment target of 36 patients; top-line results with 46 patients on track for December ’26
Building a rheumatology franchise with DNTH212 across our first three prioritized indications of Sjögren’s Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM);
Phase 1 healthy volunteer data anticipated by YE’26
Advancing DNTH312, an internally developed, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL for severe autoimmune diseases; DNTH312 aims to be Phase 1 ready by YE’27
Approximately $1.2 billion of cash as of June 30, 2026 provides expected runway into 2030
New York City and Waltham, Mass., August 4, 2026 – Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the second quarter ending June 30, 2026, and provided an update on other recent business achievements.
“Our strong execution in the first half of 2026 reflects the continued focus and discipline of the Dianthus team as we advance both claseprubart and DNTH212 for severe autoimmune diseases,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. “With the initiation of our Phase 3 EMERGE registrational trial in gMG, excellent interim results from Part A of our Phase 3 CAPTIVATE trial in CIDP, and completion of enrollment in the Phase 2 MoMeNtum trial in MMN with top-line results expected in December, claseprubart continues to demonstrate its potential as a best-in-disease, pipeline-in-a-product opportunity. In addition, we anticipate Phase 1 healthy volunteer data for DNTH212 by year end. We continue to strengthen our leadership position in autoimmune diseases with today’s announcement of the addition of our innovative, internally
1
www.dianthustx.com 7 Times Square, Floor 43 New York, NY 10036
developed, first-in-class, next generation, highly potent and half-life extended bifunctional fusion protein, DNTH312.”
Claseprubart: Potential Best-in-Disease aC1s Inhibitor for Neuromuscular Diseases
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks. Claseprubart has the potential to be a best-in-disease pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
Generalized Myasthenia Gravis (gMG)
• Phase 3 EMERGE trial initiated, with top-line results expected in 2H’28: A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W S.C. and 300mg/2mL Q4W S.C. in gMG patients was initiated in June, with top-line results expected in 2H’28.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• 75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial, exceeding the target response rate of 50% or greater based on precedent set with aC1s inhibition. Results were consistent and clinically meaningful across multiple efficacy measures. Claseprubart was generally well tolerated with no related serious infections, no clinical symptoms of drug-induced lupus (DIL), no related serious adverse events (SAEs) or discontinuations due to safety. Dianthus expects to provide CAPTIVATE Part B top-line guidance by YE’26.
Multifocal Motor Neuropathy (MMN)
• Enrollment completed, exceeding the enrollment target, in the Phase 2 MoMeNtum trial, with top-line results on track for December ‘26: The MoMeNtum trial, a global, randomized, double-blind, placebo-controlled Phase 2 trial in patients with MMN, exceeded its original enrollment target of 36 patients. Top-line results with 46 patients are on track for December ’26.
All Programs
• Claseprubart presentat
May 5, 2026 · 100% conf.
1D
-0.70%
$89.61
Act: +0.20%
5D
-9.95%
$81.27
Act: -4.53%
20D
+1.26%
$91.37
Act: -5.84%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.ce06d217.1784334149.a75536d8
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
This page provides Dianthus Therapeutics Inc. (DNTH) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on DNTH's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.